Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Intra-Cellular Therapies Inc (NASDAQ: ITCI) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Intra-Cellular Therapies Inc (NASDAQ: ITCI) concerning whether a series of statements by Intra-Cellular Therapies Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On September 28, 2016, Intra-Cellular revealed its phase III trial of its schizophrenia drug was unsuccessful and that it failed to reduce patients' schizophrenia symptoms.

Following this news, NASDAQ: ITCI dropped in early morning trading on September 29, 2016.

Based in New York, New York, Intra-Cellular Therapies Inc discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system.

If you purchased shares of Intra-Cellular Therapies Inc (NASDAQ: ITCI) on or before September 28, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185